CONTEXT: Although drug-eluting stents reduce restenosis rates relative to bare-metal stents, concerns have been raised that drug-eluting stents may also be associated with an increased risk of stent thrombosis. Our study focused on the effect of stent type on population-based interventional outcomes. OBJECTIVE: To compare outcomes of Medicare beneficiaries who underwent nonemergent coronary stenting before and after the availability of drug-eluting stents. DESIGN, SETTING, AND PATIENTS: Observational study of 38,917 Medicare patients who underwent nonemergent coronary stenting from October 2002 through March 2003 when only bare-metal stents were available (bare-metal stent era cohort) and 28,086 similar patients who underwent coronary stenting from September through December 2003, when 61.5% of patients received a drug-eluting stent and 38.5% received a bare-metal stent (drug-eluting stent era cohort). Follow-up data were available through December 31, 2005. MAIN OUTCOME MEASURES: Coronary revascularization (percutaneous coronary intervention, coronary artery bypass surgery), ST-elevation myocardial infarction, survival through 2 years of follow-up. RESULTS: Relative to the bare-metal stent era, patients treated in the drug-eluting stent era had lower 2-year risks for repeat percutaneous coronary interventions (17.1% vs 20.0%, P < .001) and coronary artery bypass surgery (2.7% vs 4.2%, P < .01). The difference in need for repeat revascularization procedures between these 2 eras remained significant after risk adjustment (hazard ratio, 0.82; 95% confidence interval, 0.79-0.85). There was no difference in unadjusted mortality risks at 2 years (8.4% vs 8.4%, P =.98 ), but a small decrease in ST-elevation myocardial infarction existed (2.4% vs 2.0%, P < .001). The adjusted hazard of death or ST-elevation myocardial infarction at 2 years was similar (hazard ratio, 0.96; 95% confidence interval, 0.92-1.01). CONCLUSION: The widespread adoption of drug-eluting stents into routine practice was associated with a decline in the need for repeat revascularization procedures and had similar 2-year risks for death or ST-elevation myocardial infarction to bare-metal stents.
CONTEXT: Although drug-eluting stents reduce restenosis rates relative to bare-metal stents, concerns have been raised that drug-eluting stents may also be associated with an increased risk of stent thrombosis. Our study focused on the effect of stent type on population-based interventional outcomes. OBJECTIVE: To compare outcomes of Medicare beneficiaries who underwent nonemergent coronary stenting before and after the availability of drug-eluting stents. DESIGN, SETTING, AND PATIENTS: Observational study of 38,917 Medicare patients who underwent nonemergent coronary stenting from October 2002 through March 2003 when only bare-metal stents were available (bare-metal stent era cohort) and 28,086 similar patients who underwent coronary stenting from September through December 2003, when 61.5% of patients received a drug-eluting stent and 38.5% received a bare-metal stent (drug-eluting stent era cohort). Follow-up data were available through December 31, 2005. MAIN OUTCOME MEASURES: Coronary revascularization (percutaneous coronary intervention, coronary artery bypass surgery), ST-elevation myocardial infarction, survival through 2 years of follow-up. RESULTS: Relative to the bare-metal stent era, patients treated in the drug-eluting stent era had lower 2-year risks for repeat percutaneous coronary interventions (17.1% vs 20.0%, P < .001) and coronary artery bypass surgery (2.7% vs 4.2%, P < .01). The difference in need for repeat revascularization procedures between these 2 eras remained significant after risk adjustment (hazard ratio, 0.82; 95% confidence interval, 0.79-0.85). There was no difference in unadjusted mortality risks at 2 years (8.4% vs 8.4%, P =.98 ), but a small decrease in ST-elevation myocardial infarction existed (2.4% vs 2.0%, P < .001). The adjusted hazard of death or ST-elevation myocardial infarction at 2 years was similar (hazard ratio, 0.96; 95% confidence interval, 0.92-1.01). CONCLUSION: The widespread adoption of drug-eluting stents into routine practice was associated with a decline in the need for repeat revascularization procedures and had similar 2-year risks for death or ST-elevation myocardial infarction to bare-metal stents.
Authors: Donald E Cutlip; Stephan Windecker; Roxana Mehran; Ashley Boam; David J Cohen; Gerrit-Anne van Es; P Gabriel Steg; Marie-angèle Morel; Laura Mauri; Pascal Vranckx; Eugene McFadden; Alexandra Lansky; Martial Hamon; Mitchell W Krucoff; Patrick W Serruys Journal: Circulation Date: 2007-05-01 Impact factor: 29.690
Authors: Joost Daemen; Shuzou Tanimoto; Héctor M García-García; Neville Kukreja; Meike van de Sande; Georgios Sianos; Peter P T de Jaegere; Ron T van Domburg; Patrick W Serruys Journal: Am J Cardiol Date: 2007-03-06 Impact factor: 2.778
Authors: Christian Spaulding; Joost Daemen; Eric Boersma; Donald E Cutlip; Patrick W Serruys Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: Gregg W Stone; Jeffrey W Moses; Stephen G Ellis; Joachim Schofer; Keith D Dawkins; Marie-Claude Morice; Antonio Colombo; Erick Schampaert; Eberhard Grube; Ajay J Kirtane; Donald E Cutlip; Martin Fahy; Stuart J Pocock; Roxana Mehran; Martin B Leon Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: Nirat Beohar; Charles J Davidson; Kevin E Kip; Lynne Goodreau; Helen Aslanidou Vlachos; Sheridan N Meyers; Keith H Benzuly; James D Flaherty; Mark J Ricciardi; Charles L Bennett; David O Williams Journal: JAMA Date: 2007-05-09 Impact factor: 56.272
Authors: Htut K Win; Angel E Caldera; Kelly Maresh; John Lopez; Charanjit S Rihal; Manish A Parikh; Juan F Granada; Sachin Marulkar; Deborah Nassif; David J Cohen; Neal S Kleiman Journal: JAMA Date: 2007-05-09 Impact factor: 56.272
Authors: Gregg W Stone; Stephen G Ellis; Antonio Colombo; Keith D Dawkins; Eberhard Grube; Donald E Cutlip; Mark Friedman; Donald S Baim; Joerg Koglin Journal: Circulation Date: 2007-05-21 Impact factor: 29.690
Authors: Michael S Lee; Ehtisham Mahmud; Lawrence Ang; Gentian Lluri; Richard K Cheng; Joseph Aragon; Imad Sheiban Journal: J Saudi Heart Assoc Date: 2013-03-14
Authors: Jerome J Federspiel; Sally C Stearns; Brett C Sheridan; Jack J Kuritzky; Laura P D'Arcy; Daniel J Crespin; Timothy S Carey; Joseph S Rossi Journal: Am Heart J Date: 2012-08 Impact factor: 4.749
Authors: Marie Bakitas; Meredith Macmartin; Kenneth Trzepkowski; Alina Robert; Lisa Jackson; Jeremiah R Brown; James N Dionne-Odom; Alan Kono Journal: J Card Fail Date: 2013-03 Impact factor: 5.712
Authors: Pamela S Douglas; J Matthew Brennan; Kevin J Anstrom; Art Sedrakyan; Eric L Eisenstein; Ghazala Haque; David Dai; David F Kong; Bradley Hammill; Lesley Curtis; David Matchar; Ralph Brindis; Eric D Peterson Journal: J Am Coll Cardiol Date: 2009-05-05 Impact factor: 24.094